Researchers Report on Efficacy of Pfizer's Xalkori in MET-mutated Lung Cancer

Jan 13, 2020

|

NEW YORK – In an expansion cohort of the Phase I PROFILE 1001 trial, 32 percent of advanced non-small cell lung cancer patients with MET exon 14 alterations saw their tumors shrink when treated with crizotinib (Pfizer's Xalkori).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Researchers Report on Efficacy of Pfizer's Xalkori in MET-mutated Lung Cancer

To read the full story....

Breaking News

UK's NICE Will Not Recommend Osimertinib for Untreated Non-Small Cell Lung Cancer

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

T Cell Assessment in Primary Melanomas Can Help Predict Metastatic Recurrence

Genetic Testing Challenges in Oncology: Patient Told Genetic Test was Negative Turns out to be MAP Carrier

FDA Accepts Bridge Biotherapeutics' Investigational New Drug Application for Lung Cancer Drug

JP Morgan Healthcare, Day 4: Five Prime Therapeutics and Gritstone Oncology

Featured White Papers

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

What's Popular?

Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

B Cell Gene Expression Profiling May Enable Cancer Immunotherapy CDx Test

Genetic Testing Challenges in Oncology: Patient Told Genetic Test was Negative Turns out to be MAP Carrier

UK's NICE Will Not Recommend Osimertinib for Untreated Non-Small Cell Lung Cancer

Sponsorships